Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C.
Wang VE, et al. Among authors: weinberg v.
Blood Cancer Discov. 2021 Sep;2(5):434-449. doi: 10.1158/2643-3230.BCD-21-0055. Epub 2021 Jul 16.
Blood Cancer Discov. 2021.
PMID: 34514432
Free PMC article.